Response of extra-large pigment epithelial detachment to intravitreal brolucizumab injection

Response of extra-large pigment epithelial detachment to intravitreal brolucizumab injection

Purpose: To determine the role of intravitreal injection (IVI) of brolucizumab for extra-large pigment epithelial detachment (PED) secondary to macular neovascularization (MNV). Observations: A prospective, non-randomized, uncontrolled case series of three eyes of three patients with extra-large PED...

Full description

Bibliographic Details
Main Authors:	Somnath Chakraborty, Jay Umed Sheth
Format:	Article
Language:	English
Published:	Elsevier 2023-06-01
Series:	American Journal of Ophthalmology Case Reports
Subjects:	Brolucizumab Macular neovascularization Pigment epithelial detachment Anti-vascular endothelial growth factor
Online Access:	http://www.sciencedirect.com/science/article/pii/S2451993623000373

Similar Items

Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment
by: Ryo Mukai, et al.
Published: (2022-09-01)

Management of Submacular Hemorrhage Using Intravitreal Brolucizumab with Pneumatic Displacement: A Case Series
by: Somnath Chakraborty, et al.
Published: (2022-11-01)

Response to brolucizumab treatment for refractory serous pigment epithelial detachment secondary to polypoidal choroidal vasculopathy
by: Seung Wan Nam, et al.
Published: (2022-12-01)

Efficacy of a single injection of brolucizumab in neovascular age-related macular degeneration on visual acuity and micromorphometry
by: Shrinivas Joshi, et al.
Published: (2023-01-01)

Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: A real-world case series
by: Debdulal Chakraborty, et al.
Published: (2021-12-01)

Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept
by: Pallavi Tyagi, et al.
Published: (2018-06-01)

Comparison of the efficacy of Conbercept and Ranibizumab for nARMD with fibrovascular pigment epithelial detachment
by: Xiang-Gui Zhang, et al.
Published: (2022-06-01)

Progression from Type 2 Macular Neovascularization to Fibrovascular Pigment Epithelial Detachment
by: Hoang Mai LE, et al.
Published: (2021-03-01)

Role of intravitreal brolucizumab with intravitreal rtPA and pneumatic displacement for submacular hemorrhage: A case series
by: Debdulal Chakraborty, et al.
Published: (2022-03-01)

Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-Related Macular Degeneration
by: Avaylon J, et al.
Published: (2020-05-01)

Brolucizumab for Choroidal Neovascular Membrane with Pigment Epithelial Tear and Subretinal Fluid
by: Alper Bilgic, et al.
Published: (2021-05-01)

A Case of Giant Macular Hole Progression after Rupture of a Giant Retinal Pigment Epithelial Detachment
by: Kosuke Nagaoka, et al.
Published: (2019-06-01)

Case report of a secondary macular hole closure after intravitreal bevacizumab therapy in a patient with retinal pigment epithelial detachment
by: Marcus Werner Storch, et al.
Published: (2017-01-01)

Meticulous multimodal analysis of aflibercept therapy for submacular vascularized pigment epithelial detachment associated with neovascular AMD in a prospective case series, the EVEN study
by: Clement K. Chan, et al.
Published: (2020-12-01)

Early OCTA Changes of Type 3 Macular Neovascularization Following Brolucizumab Intravitreal Injections
by: Anthony Gigon, et al.
Published: (2022-08-01)

Short-Term Effects of Brolucizumab in the Treatment of Wet Age-Related Macular Degeneration or Polypoidal Choroidopathy Refractory to Previous Anti-Vascular Endothelial Growth Factor Therapy
by: Alan Y. Hsu, et al.
Published: (2022-11-01)

Intravitreal Brolucizumab in Patients with Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
by: Ashwin Gupta, et al.
Published: (2022-01-01)

Geographic Atrophy after Reabsorption of Pigment Epithelial Detachment (GARPED) study
by: Enoch T. Peng, et al.
Published: (2023-05-01)

Brolucizumab in age-related macular neovascularization (BRAIN study): Efficacy, optical coherence tomography biomarkers, and safety profile
by: Supriya Dabir, et al.
Published: (2024-01-01)

Full thickness macular hole with subfoveal pigment epithelial detachment in chronic central serous chorioretinopathy: A therapeutic challenge
by: George J Manayath, et al.
Published: (2023-01-01)

Choroidal Effusion following Intravitreal Brolucizumab Injection: A Case Report
by: Ha Eun Sim, et al.
Published: (2022-03-01)

Intravitreal Injection of Brolucizumab for Recalcitrant Macular Edema due to Central Retinal Vein Occlusion: A Small Case Series
by: Debdulal Chakraborty, et al.
Published: (2022-11-01)

Retinal pigment epithelial atrophy following indocyanine green dye-assisted surgery for serous macular detachment
by: Hussain Nazimul, et al.
Published: (2008-01-01)

Retinal Pigment Epithelial Detachment in Age-Related Macular Degeneration
by: Michael Karampelas, et al.
Published: (2020-08-01)

First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration
by: Alaa Din Abdin, et al.
Published: (2022-05-01)

The Efficacy and Safety of Brolucizumab for the Treatment of nAMD: A Systematic Review and Meta-Analysis
by: Junlan Chuan, et al.
Published: (2022-05-01)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study
by: Chakraborty D, et al.
Published: (2021-09-01)

Long-Term Visual/Anatomic Outcome in Patients with Fovea-Involving Fibrovascular Pigment Epithelium Detachment Presenting Choroidal Neovascularization on Optical Coherence Tomography Angiography
by: Kyung Tae Kim, et al.
Published: (2020-06-01)

Side Effects of Brolucizumab
by: Tahmineh Motevasseli, et al.
Published: (2021-10-01)

Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice
by: Andrea Montesel, et al.
Published: (2021-11-01)

A novel small molecule anti-VEGF drug Brolucizumab in the treatment of neovascular age-related macular degeneration
by: Tong Wu, et al.
Published: (2022-05-01)

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
by: Nicola Ferrante, et al.
Published: (2022-04-01)

One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment
by: Hironori Takahashi, et al.
Published: (2024-04-01)

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye
by: Emilia Maggio, et al.
Published: (2022-09-01)

Autologous full-thickness RPE-choroid graft to treat high-risk drusenoid pigment epithelial detachment without CNV
by: Sillen, Hedwig, et al.
Published: (2020-04-01)

Evaluating photodynamic therapy versus brolucizumab as a second-line treatment for polypoidal choroidal vasculopathy
by: Ryoh Funatsu, et al.
Published: (2024-04-01)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study – Fifty-Two-Week Outcomes
by: Chakraborty D, et al.
Published: (2022-12-01)

Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration
by: Sara J. Haug, et al.
Published: (2020-06-01)

Retinal arterial occlusive vasculitis after multiple intravitreal brolucizumab injections for diabetic macular edema
by: Takao Hirano, et al.
Published: (2023-03-01)

Complete Resolution of a Giant Pigment Epithelial Detachment Secondary to Exudative Age-Related Macular Degeneration after a Single Intravitreal Ranibizumab (Lucentis) Injection: Results Documented by Optical Coherence Tomography
by: Eleni Loukianou, et al.
Published: (2010-12-01)